title: An economic analysis: is fidaxomicin worth the cost?
authors.affiliation: Healthcare Economics, Quality and Outcomes, Optimer Pharmaceuticals, Inc, Jersey City, New Jersey.
authors.forename: Hemal
authors.initials: H
authors.lastname: Shah
authors.forename: Joseph J
authors.initials: JJ
authors.lastname: Doyle
authors.forename: Daniel A
authors.initials: DA
authors.lastname: Belletti
mesh_terms: D000617:Aminoglycosides / Q000191:economics* / Q000627:therapeutic use*; D000900:Anti-Bacterial Agents / Q000191:economics* / Q000627:therapeutic use*; D016360:Clostridioides difficile / Q000302:isolation & purification*; D003015:Clostridium Infections / Q000188:drug therapy*; D005260:Female; D006801:Humans; D008297:Male
chemical_list: D000617:Aminoglycosides; D000900:Anti-Bacterial Agents